سبيرابريل

Chemical data

Formula

C22H30N2O5S2

Molecular weight

466.6 g/mol

IUPAC name

(8S)-7-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid

SMILES

CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3(C[C@H]2C(=O)O)SCCS3

InChIKey

HRWCVUIFMSZDJS-SZMVWBNQSA-N

XLogP

0.9

Polar surface area

147 Ų

H-bond donors

2

H-bond acceptors

8

Formal charge

0

via PubChem

Drug data · ChEMBL

Max clinical phase

Approved

Molecule type

Small molecule

First approval

1994

Admin. routes

oral

Indications

cardiovascular disease

via ChEMBL · EBI

• Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension.Drugs · 1995
• Efficacy and safety of spirapril in mild-to-moderate hypertension.Journal of cardiovascular pharmacology · 1999
• Angiotensin-converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: A systematic review, and network meta-analysis.Journal of clinical hypertension (Greenwich, Conn.) · 2023
• Comparison of efficacy of spirapril and enalapril in control of mild-to-moderate hypertension.Cardiovascular drugs and therapy · 1997
• ACE inhibition in chronic renal failure and in the treatment of diabetic nephropathy: focus on spirapril.Journal of cardiovascular pharmacology · 1999

via PubMed

Wikidata facts

Subclass of

chemical compound

Mass

466.16

Has use

medication

via Wikidata · CC0